+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027

  • PDF Icon

    Report

  • 162 Pages
  • December 2022
  • Region: Global
  • TechNavio
  • ID: 5398478
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the chronic obstructive pulmonary disease drugs market and is forecast to grow by $6654.49 mn during 2022-2027, accelerating at a CAGR of 6.09% during the forecast period. The publisher's report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of COPD, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.

The publisher's chronic obstructive pulmonary disease drugs market is segmented as below

By Product

  • Combination therapy
  • Monotherapy

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and the growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The publisher's report on the chronic obstructive pulmonary disease drugs market covers the following areas:

  • Chronic obstructive pulmonary disease drugs market sizing
  • Chronic obstructive pulmonary disease drugs market forecast
  • Chronic obstructive pulmonary disease drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Ltd., Philip Morris International Inc., Shionogi and Co. Ltd., Sumitomo Pharma Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size
4.1 Global chronic obstructive pulmonary disease drugs market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global chronic obstructive pulmonary disease drugs market 2017 - 2021 ($ million)
4.2 Product Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
4.3 Distribution channel Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2022-2027 (%)
Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Combination therapy - Market size and forecast 2022-2027
Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
6.4 Monotherapy - Market size and forecast 2022-2027
Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Product
Exhibit 42: Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%)
7.2 Comparison by Distribution Channel
Exhibit 45: Chart on Comparison by Distribution Channel
Exhibit 46: Data Table on Comparison by Distribution Channel
7.3 Hospital pharmacies - Market size and forecast 2022-2027
Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
7.4 Retail pharmacies - Market size and forecast 2022-2027
Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
7.5 Online pharmacies - Market size and forecast 2022-2027
Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 59: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape
8.1 Customer landscape overview
Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 63: Chart on Geographic comparison
Exhibit 64: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 UK - Market size and forecast 2022-2027
Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.9 Canada - Market size and forecast 2022-2027
Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.10 Germany - Market size and forecast 2022-2027
Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.11 Japan - Market size and forecast 2022-2027
Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 101: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 102: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 104: Overview on factors of disruption
11.4 Industry risks
Exhibit 105: Impact of key risks on business

12 Vendor Analysis
12.1 Vendors covered
Exhibit 106: Vendors covered
12.2 Market positioning of vendors
Exhibit 107: Matrix on vendor position and classification
12.3 AstraZeneca Plc
Exhibit 108: AstraZeneca Plc - Overview
Exhibit 109: AstraZeneca Plc - Product/Service
Exhibit 110: AstraZeneca Plc - Key news
Exhibit 111: AstraZeneca Plc - Key offerings
12.4 Boehringer Ingelheim International GmbH
Exhibit 112: Boehringer Ingelheim International GmbH - Overview
Exhibit 113: Boehringer Ingelheim International GmbH - Business segments
Exhibit 114: Boehringer Ingelheim International GmbH - Key news
Exhibit 115: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 116: Boehringer Ingelheim International GmbH - Segment focus
12.5 Cadila Pharmaceuticals Ltd.
Exhibit 117: Cadila Pharmaceuticals Ltd. - Overview
Exhibit 118: Cadila Pharmaceuticals Ltd. - Product/Service
Exhibit 119: Cadila Pharmaceuticals Ltd. - Key offerings
12.6 Cipla Ltd.
Exhibit 120: Cipla Ltd. - Overview
Exhibit 121: Cipla Ltd. - Business segments
Exhibit 122: Cipla Ltd. - Key news
Exhibit 123: Cipla Ltd. - Key offerings
Exhibit 124: Cipla Ltd. - Segment focus
12.7 Exela Pharma Sciences LLC
Exhibit 125: Exela Pharma Sciences LLC - Overview
Exhibit 126: Exela Pharma Sciences LLC - Product/Service
Exhibit 127: Exela Pharma Sciences LLC - Key offerings
12.8 GlaxoSmithKline Plc
Exhibit 128: GlaxoSmithKline Plc - Overview
Exhibit 129: GlaxoSmithKline Plc - Business segments
Exhibit 130: GlaxoSmithKline Plc - Key offerings
Exhibit 131: GlaxoSmithKline Plc - Segment focus
12.9 Lupin Ltd.
Exhibit 132: Lupin Ltd. - Overview
Exhibit 133: Lupin Ltd. - Product/Service
Exhibit 134: Lupin Ltd. - Key news
Exhibit 135: Lupin Ltd. - Key offerings
12.10 Merck and Co. Inc.
Exhibit 136: Merck and Co. Inc. - Overview
Exhibit 137: Merck and Co. Inc. - Business segments
Exhibit 138: Merck and Co. Inc. - Key news
Exhibit 139: Merck and Co. Inc. - Key offerings
Exhibit 140: Merck and Co. Inc. - Segment focus
12.11 Mundipharma International Ltd.
Exhibit 141: Mundipharma International Ltd. - Overview
Exhibit 142: Mundipharma International Ltd. - Product/Service
Exhibit 143: Mundipharma International Ltd. - Key offerings
12.12 Novartis AG
Exhibit 144: Novartis AG - Overview
Exhibit 145: Novartis AG - Business segments
Exhibit 146: Novartis AG - Key offerings
Exhibit 147: Novartis AG - Segment focus
12.13 Shionogi and Co. Ltd.
Exhibit 148: Shionogi and Co. Ltd. - Overview
Exhibit 149: Shionogi and Co. Ltd. - Product/Service
Exhibit 150: Shionogi and Co. Ltd. - Key offerings
12.14 Sumitomo Pharma Co. Ltd.
Exhibit 151: Sumitomo Pharma Co. Ltd. - Overview
Exhibit 152: Sumitomo Pharma Co. Ltd. - Business segments
Exhibit 153: Sumitomo Pharma Co. Ltd. - Key offerings
Exhibit 154: Sumitomo Pharma Co. Ltd. - Segment focus
12.15 Teva Pharmaceutical Industries Ltd.
Exhibit 155: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 156: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 157: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 159: Teva Pharmaceutical Industries Ltd. - Segment focus
12.16 Theravance Biopharma Inc.
Exhibit 160: Theravance Biopharma Inc. - Overview
Exhibit 161: Theravance Biopharma Inc. - Product/Service
Exhibit 162: Theravance Biopharma Inc. - Key offerings
12.17 Viatris Inc.
Exhibit 163: Viatris Inc. - Overview
Exhibit 164: Viatris Inc. - Business segments
Exhibit 165: Viatris Inc. - Key offerings
Exhibit 166: Viatris Inc. - Segment focus

13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 167: Inclusions checklist
Exhibit 168: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 169: Currency conversion rates for US$
13.4 Research methodology
Exhibit 170: Research methodology
Exhibit 171: Validation techniques employed for market sizing
Exhibit 172: Information sources
13.5 List of abbreviations
Exhibit 173: List of abbreviationsList of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 18: Historic Market Size - Data Table on Global chronic obstructive pulmonary disease drugs market 2017 - 2021 ($ million)
Exhibits 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
Exhibits 20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2022 and 2027
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 29: Chart on Market condition - Five forces 2022 and 2027
Exhibits 30: Chart on Product - Market share 2022-2027 (%)
Exhibits 31: Data Table on Product - Market share 2022-2027 (%)
Exhibits 32: Chart on Comparison by Product
Exhibits 33: Data Table on Comparison by Product
Exhibits 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
Exhibits 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
Exhibits 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
Exhibits 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
Exhibits 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
Exhibits 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
Exhibits 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
Exhibits 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
Exhibits 42: Market opportunity by Product ($ million)
Exhibits 43: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibits 44: Data Table on Distribution Channel - Market share 2022-2027 (%)
Exhibits 45: Chart on Comparison by Distribution Channel
Exhibits 46: Data Table on Comparison by Distribution Channel
Exhibits 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
Exhibits 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
Exhibits 59: Market opportunity by Distribution Channel ($ million)
Exhibits 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 63: Chart on Geographic comparison
Exhibits 64: Data Table on Geographic comparison
Exhibits 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 67: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 81: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits 83: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits 84: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 87: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits 88: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibits 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibits 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibits 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
Exhibits 101: Market opportunity By Geographical Landscape ($ million)
Exhibits 102: Impact of drivers and challenges in 2022 and 2027
Exhibits 103: Overview on Criticality of inputs and Factors of differentiation
Exhibits 104: Overview on factors of disruption
Exhibits 105: Impact of key risks on business
Exhibits 106: Vendors covered
Exhibits 107: Matrix on vendor position and classification
Exhibits 108: AstraZeneca Plc - Overview
Exhibits 109: AstraZeneca Plc - Product/Service
Exhibits 110: AstraZeneca Plc - Key news
Exhibits 111: AstraZeneca Plc - Key offerings
Exhibits 112: Boehringer Ingelheim International GmbH - Overview
Exhibits 113: Boehringer Ingelheim International GmbH - Business segments
Exhibits 114: Boehringer Ingelheim International GmbH - Key news
Exhibits 115: Boehringer Ingelheim International GmbH - Key offerings
Exhibits 116: Boehringer Ingelheim International GmbH - Segment focus
Exhibits 117: Cadila Pharmaceuticals Ltd. - Overview
Exhibits 118: Cadila Pharmaceuticals Ltd. - Product/Service
Exhibits 119: Cadila Pharmaceuticals Ltd. - Key offerings
Exhibits 120: Cipla Ltd. - Overview
Exhibits 121: Cipla Ltd. - Business segments
Exhibits 122: Cipla Ltd. - Key news
Exhibits 123: Cipla Ltd. - Key offerings
Exhibits 124: Cipla Ltd. - Segment focus
Exhibits 125: Exela Pharma Sciences LLC - Overview
Exhibits 126: Exela Pharma Sciences LLC - Product/Service
Exhibits 127: Exela Pharma Sciences LLC - Key offerings
Exhibits 128: GlaxoSmithKline Plc - Overview
Exhibits 129: GlaxoSmithKline Plc - Business segments
Exhibits 130: GlaxoSmithKline Plc - Key offerings
Exhibits 131: GlaxoSmithKline Plc - Segment focus
Exhibits 132: Lupin Ltd. - Overview
Exhibits 133: Lupin Ltd. - Product/Service
Exhibits 134: Lupin Ltd. - Key news
Exhibits 135: Lupin Ltd. - Key offerings
Exhibits 136: Merck and Co. Inc. - Overview
Exhibits 137: Merck and Co. Inc. - Business segments
Exhibits 138: Merck and Co. Inc. - Key news
Exhibits 139: Merck and Co. Inc. - Key offerings
Exhibits 140: Merck and Co. Inc. - Segment focus
Exhibits 141: Mundipharma International Ltd. - Overview
Exhibits 142: Mundipharma International Ltd. - Product/Service
Exhibits 143: Mundipharma International Ltd. - Key offerings
Exhibits 144: Novartis AG - Overview
Exhibits 145: Novartis AG - Business segments
Exhibits 146: Novartis AG - Key offerings
Exhibits 147: Novartis AG - Segment focus
Exhibits 148: Shionogi and Co. Ltd. - Overview
Exhibits 149: Shionogi and Co. Ltd. - Product/Service
Exhibits 150: Shionogi and Co. Ltd. - Key offerings
Exhibits 151: Sumitomo Pharma Co. Ltd. - Overview
Exhibits 152: Sumitomo Pharma Co. Ltd. - Business segments
Exhibits 153: Sumitomo Pharma Co. Ltd. - Key offerings
Exhibits 154: Sumitomo Pharma Co. Ltd. - Segment focus
Exhibits 155: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 156: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 157: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 158: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 159: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 160: Theravance Biopharma Inc. - Overview
Exhibits 161: Theravance Biopharma Inc. - Product/Service
Exhibits 162: Theravance Biopharma Inc. - Key offerings
Exhibits 163: Viatris Inc. - Overview
Exhibits 164: Viatris Inc. - Business segments
Exhibits 165: Viatris Inc. - Key offerings
Exhibits 166: Viatris Inc. - Segment focus
Exhibits 167: Inclusions checklist
Exhibits 168: Exclusions checklist
Exhibits 169: Currency conversion rates for US$
Exhibits 170: Research methodology
Exhibits 171: Validation techniques employed for market sizing
Exhibits 172: Information sources
Exhibits 173: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global chronic obstructive pulmonary disease drugs market: AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Ltd., Philip Morris International Inc., Shionogi and Co. Ltd., Sumitomo Pharma Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is expanding research in curative approaches.'

According to the report, one of the major drivers for this market is the rising prevalence of COPD.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc
  • Exela Pharma Sciences LLC
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Innoviva Inc.
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Mundipharma International Ltd.
  • Novartis AG
  • Theravance Biopharma Inc.
  • Vertex Pharmaceuticals Inc.
  • Viatris Inc.
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Ltd.
  • CHIESI Farmaceutici SpA
  • Cipla Ltd.
  • Philip Morris International Inc.
  • Shionogi and Co. Ltd.
  • Sumitomo Pharma Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.